Pirarubicin
- Generic Name
- Pirarubicin
- Drug Type
- Small Molecule
- Chemical Formula
- C32H37NO12
- CAS Number
- 72496-41-4
- Unique Ingredient Identifier
- D58G680W0G
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Phase 2
Recruiting
- Conditions
- Osteosarcoma
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06714383
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
Not Applicable
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT05287308
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Breast Cancer Organoids
- Interventions
- Drug: PattozumabDrug: Ear particles
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
Combination Therapy of Anthracyclines for Children With Nephroblastoma
Phase 4
Not yet recruiting
- Conditions
- 0.5-14 Year Old Children With Nephroblastoma
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03892330
- Locations
- 🇨🇳
Shenjing Hospital, Shenyang, Liaoning, China
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Phase 2
Withdrawn
- Conditions
- Progression-free SurvivalOverall SurvivalToxicity
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Peking University People's Hospital
- Registration Number
- NCT03342300
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients
Phase 2
- Conditions
- NephroureterectomyUpper Tract Urothelial CarcinomaBladder Recurrence
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02923557
- Locations
- 🇨🇳
Peking University Frist Hospital, Beijing, Beijing, China
Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer
Phase 4
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02903524
- Locations
- 🇨🇳
Fourth Hospital of Hebei Medical University, Shi Jiazhuang, Hebei, China
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02740426
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer
Phase 3
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- 307 Hospital of PLA
- Target Recruit Count
- 104
- Registration Number
- NCT02613026
- Locations
- 🇨🇳
The fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Hunan Provincial People's Hospital, Changsha, Hunan, China
🇨🇳Xiangya Hospital, Central South University, Changsha, Hunan, China
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
Phase 2
Withdrawn
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Guangxi Medical University
- Registration Number
- NCT02585479
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath